Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.

Alexandra Audemard-VergerAmélie Le GougeVincent PestreJohan CourjonVincent LangloisMarc-Olivier VareilMathilde DevauxBoris BienvenuVincent LeroyRadjiv GoulabchandLéa ColombainAdrien BigotThomas GuimardYoucef DouadiGeoffrey UrbanskiJean François FaucherLaurence MaulinBertrand LiogerJean-Philippe TalarminMatthieu GrohJoseph EmmerichSophie DeriazNicole Ferreira-MaldentAnn-Rose CookCéline LengelléHélène BourgoinArsène MekinianAchille AoubaFrançois MaillotAgnès Caille

Published in: PloS one (2022)

This trial did not show efficacy of anakinra in patients with COVID-19. Furthermore, contrary to our hypothesis, we found that anakinra was inferior to oSOC in patients with moderate COVID-19 pneumonia.

Keyphrases

coronavirus disease
sars cov
clinical trial
study protocol
respiratory syndrome coronavirus
high intensity
case report
randomized controlled trial
sleep quality
intensive care unit
open label
respiratory failure